The potential of the B cell lymphoma-2 (Bcl-2) family of apoptosis inhibitors as a cancer target has attracted a number of biotech companies. However, survivin, an apoptosis inhibitor overexpressed in common human cancers and further downstream in the cell death pathway than Bcl-2, may prove to be more effective in diagnosing and treating particular tumor types. Two papers published last week support the use of survivin to detect bladder cancer